论文部分内容阅读
目的:研究基因重组γ干扰素在治疗变应性鼻炎中的作用。方法:采用随机对照研究方法将60例变应性鼻炎患者分成两组.每组30例,一组予常规脱敏治疗(对照组),另一组予常规脱敏治疗加基因重组γ干扰素治疗(实验组),6个月后比较两组的症状评分、血清白细胞介素-4(IL-4)、嗜酸粒细胞阳离子蛋白(ECP)水平。结果:对照组治疗前、后症状评分分别为10.6±2.3和4.2±1.8,血清IL-4水平分别为(545.3±86.2)ng/L和(320.4±76.3)ng/L,ECP水平分别为(24.3±8.2)μg/L和(12.4±6.3)μg/L;实验组治疗前、后症状评分分别为10.8±2.7和3.5±1.6,血清IL-4水平分别为(547.8±84.6)ng/L和(280.4±87.3)ng/L,ECP水平分别为(25.1±7.7)μg/L和(10.4±5.1)μg/L。实验组治疗后症状评分、IL-4和ECP水平均低于对照组(均P<0.05)。结论:基因重组γ干扰素能改善变应性鼻炎症状.降低血清IL-4、ECP水平,在变应性鼻炎的治疗中发挥着免疫调节作用。
Objective: To study the role of recombinant interferon gamma in the treatment of allergic rhinitis. Methods: Sixty patients with allergic rhinitis were divided into two groups according to a randomized controlled study: 30 cases in each group, one group received routine desensitization treatment (control group), the other group received routine desensitization plus gene recombinant interferon gamma (Experimental group). After six months, the symptom score, serum interleukin-4 (IL-4) and eosinophil cationic protein (ECP) were compared between the two groups. Results: The symptom scores of the control group before and after treatment were 10.6 ± 2.3 and 4.2 ± 1.8, respectively, and the levels of serum IL-4 were (545.3 ± 86.2) ng / L and (320.4 ± 76.3) ng / L, respectively 24.3 ± 8.2) μg / L and (12.4 ± 6.3) μg / L, respectively. The scores of symptoms in the experimental group before and after treatment were 10.8 ± 2.7 and 3.5 ± 1.6, respectively, and the serum IL-4 levels were 547.8 ± 84.6ng / And (280.4 ± 87.3) ng / L, respectively. ECP levels were (25.1 ± 7.7) μg / L and (10.4 ± 5.1) μg / L, respectively. Symptom scores, IL-4 and ECP levels in experimental group were lower than those in control group (all P <0.05). CONCLUSION: Recombinant gamma interferon can improve the symptoms of allergic rhinitis, reduce the serum levels of IL-4 and ECP, and play an immunomodulatory role in the treatment of allergic rhinitis.